Fjarde AP Fonden Fourth Swedish National Pension Fund Acquires 1,122 Shares of Vertex Pharmaceuticals Incorporated (VRTX)

Fjarde AP Fonden Fourth Swedish National Pension Fund increased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.0% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 58,372 shares of the pharmaceutical company’s stock after purchasing an additional 1,122 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Vertex Pharmaceuticals were worth $8,875,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Comerica Bank grew its stake in Vertex Pharmaceuticals by 1.1% during the third quarter. Comerica Bank now owns 60,413 shares of the pharmaceutical company’s stock worth $9,034,000 after buying an additional 669 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Vertex Pharmaceuticals by 0.6% during the third quarter. Bank of New York Mellon Corp now owns 1,994,410 shares of the pharmaceutical company’s stock worth $303,230,000 after buying an additional 12,454 shares during the last quarter. Teacher Retirement System of Texas grew its stake in Vertex Pharmaceuticals by 27.4% during the third quarter. Teacher Retirement System of Texas now owns 3,391 shares of the pharmaceutical company’s stock worth $516,000 after buying an additional 730 shares during the last quarter. Rhumbline Advisers grew its stake in Vertex Pharmaceuticals by 1.5% during the third quarter. Rhumbline Advisers now owns 427,457 shares of the pharmaceutical company’s stock worth $64,991,000 after buying an additional 6,137 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. grew its stake in Vertex Pharmaceuticals by 2,262.7% during the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 85,339 shares of the pharmaceutical company’s stock worth $12,975,000 after buying an additional 81,727 shares during the last quarter. 92.79% of the stock is owned by hedge funds and other institutional investors.

In related news, COO Ian F. Smith sold 2,155 shares of the business’s stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $150.00, for a total transaction of $323,250.00. Following the transaction, the chief operating officer now owns 43,043 shares in the company, valued at approximately $6,456,450. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Ian F. Smith sold 75,000 shares of the business’s stock in a transaction on Tuesday, October 31st. The shares were sold at an average price of $145.06, for a total transaction of $10,879,500.00. Following the transaction, the chief operating officer now owns 114,188 shares in the company, valued at approximately $16,564,111.28. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 220,094 shares of company stock worth $32,074,719. Insiders own 1.80% of the company’s stock.

Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) traded down $0.21 on Wednesday, reaching $147.82. 1,209,100 shares of the company’s stock were exchanged, compared to its average volume of 1,821,351. Vertex Pharmaceuticals Incorporated has a 52-week low of $71.46 and a 52-week high of $167.85. The company has a quick ratio of 3.14, a current ratio of 3.28 and a debt-to-equity ratio of 0.01. The company has a market cap of $37,437.20, a price-to-earnings ratio of 246.72, a price-to-earnings-growth ratio of 3.76 and a beta of 1.63.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Wednesday, October 25th. The pharmaceutical company reported $0.53 EPS for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.49. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The company had revenue of $578.20 million for the quarter, compared to analyst estimates of $522.07 million. During the same period in the prior year, the firm posted $0.16 EPS. The company’s quarterly revenue was up 39.7% on a year-over-year basis. research analysts expect that Vertex Pharmaceuticals Incorporated will post 0.72 EPS for the current fiscal year.

VRTX has been the topic of several research analyst reports. Stifel Nicolaus increased their price target on shares of Vertex Pharmaceuticals from $130.00 to $154.00 and gave the company a “buy” rating in a research note on Tuesday, July 18th. J P Morgan Chase & Co set a $184.00 price target on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, July 27th. Raymond James Financial, Inc. raised shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $181.00 price target on the stock in a research note on Wednesday, July 19th. Zacks Investment Research cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 24th. Finally, Vetr lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $181.00 price objective on the stock. in a report on Monday, September 4th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-three have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $173.15.

TRADEMARK VIOLATION WARNING: “Fjarde AP Fonden Fourth Swedish National Pension Fund Acquires 1,122 Shares of Vertex Pharmaceuticals Incorporated (VRTX)” was reported by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.themarketsdaily.com/2017/11/15/fjarde-ap-fonden-fourth-swedish-national-pension-fund-acquires-1122-shares-of-vertex-pharmaceuticals-incorporated-vrtx.html.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply